Анемия хронических заболеваний. Анемия хронических заболеваний
 Скачать 0.53 Mb.
|
|
62. 96 Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a urinary antimicrobial peptide synthe- sized in the liver. J Biol Chem 2001;276:7806-10. 97 Ganz T. Hepcidin - A peptide hormone at the interface of innate immunity and iron metabo- lism. Curr Top Microbiol Immunol 2006;306:183-98. 98 Pigeon C1, Ilyin G, Courselaud B, Leroyer P. et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload // J Biol Chem. 2001 Mar 16;276(11):7811-9. Epub 2000 Dec 11. 99 De Domenico I, Ward DM, Langelier C, Vaughn MB, Nemeth E, Sundquist WI, et al. The mo- lecular mechanism of hepcidin-mediated ferroportin down-regulation. Mol Biol Cell 2007;18:2569-78. 100 de Oliveira Júnior WV, Sabino Ade P, Figueiredo RC, Rios DR. Inflammation and poor re- sponse to treatment with erythropoietin in chronic kidney disease // J Bras Nefrol. 2015 Apr- Jun;37(2):255-63. doi: 10.5935/0101-2800.20150039. 101 World Health Organization (2008). Worldwide prevalence of anaemia 1993–2005. Geneva: World Health Organization. ISBN 9789241596657 102 Верткин А.Л. Пациент с анемией на амбулаторном приему у терапевта // Справочник поликлинического врача.- 2014.- №4.- С.4-9 103 Новик А.А., Богданов А.Н. Анемии (от А до Я) Руководство для врачей / 2006, 320 с. 104 Сморкалова Е.В. Иммуногематологические особенности железодефицитной анемии и анемии хронических заболеваний // Автореф… канд мед.н., Уфа, 2012 105 Weiss G. Pathogenesis and treatment of anemia of chronic disease. Blood Rev,2002; 16: 87- 96 106 Skikne B.S., Punnonen K., Caldron P.H. et al. Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index // Am. J. Hematol. – 2011.- 86:923–927, 107 Kato Y, Takagi C, Tanaka J. Et al. Effect of daily subcutaneous administration of recombi- nant erythropoietin on chronic anemia in rheumatoid arthritis // Intern Med. 1994 Apr; 33(4):193-7 108 Peeters HR, Jongen-Lavrencic M, Bakker C.H. et al. Recombinant human erythropoietin im- proves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int. 1999;18(5-6):201–206. 109 Arndt U, Kaltwasser JP, Gottschalk R, Hoelzer D, Moller B. Correction of iron-deficient erythropoiesis in the treatment of anemia of chronic disease with recombinant human erythropoietin. Ann Hematol. 2005;84(3):159–166. 110 Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemo- dialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) study. Journal of the American Society of Nephrol- ogy. 2007;18(3):975–984 111 Macciò A., Madeddu C. Management of Anemia of Inflammation in the Elderly // Anemia. 2012; 2012: 563251. 112 Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down- regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627–3634 113 Song SN, Iwahashi M, Tomosugi N, Uno K, Yamana J, Yamana S, et al. Comparative evalua- tion of the effects of treatment with tocilizumab and TNF-alpha inhibitors on serum hepcidin, anemia re- sponse and disease activity in rheumatoid arthritis patients. Arthritis Res Ther. 2013;15(5):R141. 114 Isaacs JD, Harari O, Kobold U, Lee JS, Bernasconi C. Effect of tocilizumab on haematologi- cal markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis. Arthritis Res Ther. 2013;15(6):R204. 115 Schipperus M, Rijnbeek B, Reddy M. et al. CNTO328 (Anti-IL-6 mAb) Treatment Is Associ- ated with An Increase in Hemoglobin (Hb) and Decrease in Hepcidin Levels in Renal Cell Carcinoma (RCC) [abstract]. Blood. 2009;22(114):4045. 116 Hohlbaum A, Gille H, Christian J. et al. Iron mobilization and pharmacodynic marker meas- urements in non-human primates following administration of PRS-080, a novel and highly specific anti- hepcidin therapeutic. American Journal of Hematology. 2013;88(5):E41. 117 Schwoebel F, van Eijk LT, Zboralski D, Sell S, Buchner K, Maasch C, et al. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013 118 Theurl I, Schroll A, Sonnweber T. et al. Pharmacologic inhibition of hepcidin expression re- verses anemia of chronic inflammation in rats. Blood. 2011;118(18):4977–4984 119 Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, et al. Heparin: a po- tent inhibitor of hepcidin expression in vitro and in vivo. Blood. 2011;117(3):997–1004 120 Crosby JR, Gaarde WA, Egerston J, McKay R, Sun Y, Freier S, et al. Targeting hepcidin with antisense oligonucletides improves anemia endpoints in mice. Blood. 2006;108(11, Part 1):83A–84A. 121 Akinc A, Chan-Daniels A, Sehgal A, Foster D, Bettencourt BR, Hettinger J, et al. Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia. Blood. 2011;118(21):315 |